Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind, Dose-response Study to Assess the Optimal Dose as Well as Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

NCT00719511 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT00719511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00719511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind, Dose-response Study to Assess the Optimal Dose as Well as Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
December 31, 2009
Enrollment
132 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergies